据京沪深交易所披露，上周（11月3日-11月7日）5企业上会，新增2家新受理企业；4家提交IPO注册申 请，2家IPO注册获通过，2家IPO终止；5只新股上市。 与此同时，本周（11月10日-11月14日）4家公司上会迎考，2只新股安排申购。 一、IPO审核与注册进展 祺龙海洋主要从事海洋钻井隔水导管的研发、生产与销售，同时涵盖油气长输管线生产销售及水下油气 装备试验技术服务；海圣医疗主要从事麻醉、监护类医疗器械产品研发、生产和销售，产品涵盖麻醉、 监护、手术及护理医疗器械三大类；国亮新材是一家专业从事高温工业用耐火材料整体解决方案的高新 技术企业。 北交所上市委对上述三家公司提出问询的主要问题集中在业绩真实性、财务信息的真实性与准确性、客 户合作稳定性及经营业绩可持续性、控股股东的经营情况、行业政策的影响以及设备研发与产业化方 面。 比如，上市委要求祺龙海洋说明与第一大客户中海油合作是否稳定可持续，坏账计提准备是否充分；要 求海圣医疗说明带量集采、"两票制"等政策对公司经营业绩稳定性及应对措施；要求国亮新材说明应收 账款周转率逐年下降及最近一期应收账款占营收比例大幅增长的原因，2025年度盈利预测的可实现性 ...

当飞利浦首发首展的临床多核磁共振设备，首次将AI融入影像检查的每一环节时，不远处的上海馆内正展示着可陪伴可助行的养老护理机器人…… 在第八届进博会上，"黑科技"与"银发经济"的对话，勾勒出中国新产业、新业态、新商业模式的清晰图景——连续举办八年的进博会，不仅为全球企业提 供展示创新成果、拓展中国市场的重要机遇，也为激发内需市场活力、推动经济高质量发展注入新动能。 "黑科技"闪耀，新产业加速崛起 "本届进博会上，许多面向未来的创新解决方案，为中国市场注入了新活力，让中国成为了全球新技术与新理念的'首发地'。"八年来，德勤与进博会一同 成长，见证了进博会的茁壮成长。德勤中国华东区主管合伙人卢强表示，"我们看到了中国市场的开放韧性，也看到了世界对于中国机遇的信心。" 作为世界上首个以进口为主题的国家级展会，进博会上，各种全球首发、亚洲首发和中国首发层出不穷，让中国大市场成为全球创新的试验场、利润场、 应用场。这些"黑科技"，不仅体现了全球产业变革的最新趋势，也成为了新产业发展的风向标。 AI加持，"银发经济"新业态悄然成型 过去，具有未来感的科技展会常被视作"年轻人主场"，本届进博会则涌现出众多面向"银发群体"的" ...

IPO Review and Registration Progress - Five companies passed the IPO review last week, including ZhiXin Co. and Shaanxi Tourism, marking the first cultural tourism IPO approval in A-shares in five years [2][3] - Shaanxi Tourism's IPO aims to raise 1.555 billion yuan for projects like cableway upgrades and performance expansion, with its main revenue sources being tourism performances and cableway operations [2] - ZhiXin Co. focuses on automotive stamping parts and related molds, with the review committee expressing concerns about market competition and revenue sustainability [3] New IPO Applications and Terminations - Two IPO applications were accepted last week, including JiaDeLi and Core Medical, with JiaDeLi aiming to raise 725 million yuan for a new production base [9][10] - Two IPO applications were terminated, including HaiChuang Optoelectronics and JianNeng Technology, due to voluntary withdrawal and status change respectively [12] New Stock Listings and Subscription Dynamics - Five new stocks were listed last week, with DanNa Bio experiencing a significant increase of nearly 500% on its first trading day [13] - This week, two new stocks are scheduled for subscription, including NanTe Technology and HaiAn Group, with NanTe aiming for a price of 8.66 yuan per share [15]

Core Insights - The eighth China International Import Expo (CIIE) showcases a blend of "black technology" and the "silver economy," highlighting new industries, business models, and the potential for high-quality economic development in China [1][5][13] Group 1: Innovations in Healthcare - Philips launched a clinical multi-nuclear magnetic resonance device that integrates AI into every aspect of imaging examinations, marking a significant advancement in medical technology [1][12] - Siemens Medical introduced a high-gradient magnetic resonance device to assist Neuralink in clinical trials for brain-machine interfaces, enabling more precise surgical procedures [4][12] - The expo featured several AI-powered healthcare products, including a photon-counting CT family aimed at improving the quality of life for Parkinson's and paralyzed patients [4][12] Group 2: Silver Economy Developments - The expo highlighted numerous technologies aimed at the elderly, addressing the diverse needs of an aging population, with the "silver economy" being a key focus area [5][6][13] - A notable innovation is the caregiving robot that can switch between robot and wheelchair modes, assisting with daily tasks and providing companionship [6][9] - Sony's AI fall detection sensor exemplifies the trend of "invisible care," offering privacy protection while ensuring timely assistance for elderly individuals [10][12] Group 3: Market Trends and Future Outlook - The CIIE serves as a platform for global companies to launch new products, making China a testing ground for innovative technologies and business models [5][13] - The integration of AI into various sectors, including healthcare and elder care, is seen as a driving force for the silver economy, with significant market potential [10][15] - The event also showcased a complete "silver economy" industry chain, from smart aids to health services, indicating a shift towards comprehensive service systems [10][12]

｜2025年11月10日 星期一｜ NO.1 恒瑞医药NewCo公司获1.85亿美元A轮融资 NO.3 精准生物自研国内首款儿童白血病CAR-T治疗产品获批上市 近日，重庆精准生物自主研发的国家一类生物新药普基奥仑赛注射液（商品名：普利得凯）正式获得国 家药品监督管理局批准上市。该药品用于治疗3至21岁CD19阳性的难治或复发（首次缓解12个月后复发 需经挽救化疗）的急性B淋巴细胞白血病患者。 点评：该产品是中国首款获批用于治疗儿童及青少年难治性或复发性 B 细胞急性淋巴细胞白血病（r/r B-ALL）的 CAR-T 细胞治疗药物。其采用人源化 CD19 单链可变区片段（scFv）设计，是目前已上 市、适用于儿童及青少年适应症的 CD19 CAR-T 产品中，唯一采用人源化修饰的产品。 NO.4 旨在"功能性治愈"乙肝，双链siRNA新药获批临床 近日，中国国家药监局药品审评中心官网公示显示，悦康科创医药和天龙药业共同申报的1类新药 YKYY013注射液获批临床，拟开发治疗慢性乙型肝炎病毒感染。公开资料显示，这是一款偶联N-乙酰 半乳糖胺（GalNAc）配体的化学合成双链siRNA药物，其通过RNA干扰作用有 ...

| 财务指标/时间 | 2024年 | 2023年 | 2022年 | | --- | --- | --- | --- | | 营业收入（万元） | 9368.84 | 1655.03 | 0.00 | | 归属母公司股东的净利润（万元） | -13181.33 | -16994.64 | -17840.12 | | 扣除非经常损益后归属母公司所有者净利润（万元） | -13397.29 | -13939.99 | -12166.07 | | 基本每股收益（元） | -0.4400 | -0.5900 | -0.8700 | | 稀释每股收益（元） | -0.4400 | -0.5900 | -0.8700 | | 加权平均净资产收益率（%） | -38.08 | -42.48 | -121.20 | | 经营活动产生的现金流量净额（万元） | -8894.81 | -10790.12 | -8091.43 | | 研发投入（万元） | | | | | 研发投入占营业收入比例（%） | | | | 注：本文系新闻报道，不构成投资建议 核心医疗成立于2016年8月，公司是一家致力于提供更全面、更创新、更优质的人 ...

智通财经APP获悉，11月6日，上交所披露，泉州嘉德利电子材料股份公司(嘉德利)、深圳核心医疗科技股份有限公司(核心医疗)上交所IPO申请已获受理。 | 泉州嘉德利电子材料股份公司 | 主板 已受理 | 福建 | 计算机、i | | --- | --- | --- | --- | | 深圳核心医疗科技股份有限公司 | 科创板 已受理 | 广东 | 专用设备: | 据招股书，嘉德利是专注从事 BOPP 电工膜研发、生产和销售的国家级专精特新"小巨人"企业和高新技术企业，深耕 BOPP 电工膜领域超过 20 年，拥有丰 富且极具竞争力的产品储备矩阵。通过长期技术研发和工艺积累，公司在产品超薄化、耐高温和耐高压等关键技术指标方面不断取得突破，目前在不同规格 产品系列中，可分别实现 1.9µm 超薄膜、125℃超耐温膜、900V 超薄膜和 2,000V 特种脉冲薄膜等标志性产品的稳定量产，这些产品广泛应用在新能源汽 车、可再生能源、柔直输变电等新兴领域。 招股书显示，核心医疗是一家致力于提供更全面、更创新、更优质的人工心脏产品的创新医疗器械企业。截至招股说明书签署日，公司已布局 5 款植入式和 6 款介入式人工心脏产 ...

Core Insights - Shenzhen Core Medical Technology Co., Ltd. has received acceptance for its IPO application on the Sci-Tech Innovation Board, marking it as the first innovative medical device company to be accepted under the fifth set of listing standards since their reactivation [1][2] - The company focuses on providing comprehensive, innovative, and high-quality artificial heart products, addressing significant clinical needs in acute and chronic heart failure [1] - Core Medical has achieved key milestones and is expected to have a market value of no less than 4 billion yuan, with its main products requiring approval from relevant national authorities [1] Company Overview - Core Medical is dedicated to the iterative upgrade of artificial heart products through original innovation and key core technology breakthroughs [1] - The company meets the listing criteria outlined in the "Listing Rules," specifically requiring at least one core product to have obtained approval for Phase II clinical trials [1] Industry Context - The acceptance of Core Medical's IPO application highlights the growing market space and potential for innovative medical device companies within the healthcare sector [1][2]